Lexgenleucel-T

Drug Profile

Lexgenleucel-T

Alternative Names: Anti-HIV gene therapy - VIRxSYS; VRX 496; VRX496

Latest Information Update: 01 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator VIRxSYS Corporation
  • Developer University of Pennsylvania; VIRxSYS Corporation
  • Class Antivirals; Gene therapies; T lymphocyte cell therapies
  • Mechanism of Action HIV replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II HIV infections

Most Recent Events

  • 01 Sep 2015 Phase-II development for HIV infections is ongoing in USA
  • 22 Jul 2010 Lexgenleucel-T is still in phase II trials for HIV infections in USA
  • 22 May 2010 Adverse events data from a phase II trial in HIV infections released by VIRxSYS
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top